Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Equity

The The Equity of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 22, 2026 is 3.71 B CNY. In the previous year, The Equity was 3.60 B CNY — a change of 3.10% (higher).

Equity

3.71 BCNY

YoY

3.10%

Last updated:

In 2025, Vcanbio Cell & Gene Engineering Corp's equity was 3.71 B CNY, a 3.10% increase from the 3.60 B CNY equity in the previous year.

The Vcanbio Cell & Gene Engineering Corp Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
2.77 B CNY
Jan 1, 2019
3.35 B CNY
Jan 1, 2020
3.42 B CNY
Jan 1, 2021
3.46 B CNY
Jan 1, 2022
3.56 B CNY
Jan 1, 2023
3.68 B CNY
Jan 1, 2024
3.60 B CNY
Jan 1, 2025
3.71 B CNY
The Vcanbio Cell & Gene Engineering Corp Equity history
YEAREquityYoY
3.71 BCNY+3.10%
3.60 BCNY-2.42%
3.68 BCNY+3.61%
3.56 BCNY+2.67%
3.46 BCNY+1.42%
3.42 BCNY+1.83%
3.35 BCNY+20.96%
2.77 BCNY+83.73%
1.51 BCNY-4.96%
1.59 BCNY+2.21%
1.55 BCNY+50.46%
1.03 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Vcanbio Cell & Gene Engineering Corp's Equity

Vcanbio Cell & Gene Engineering Corp's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vcanbio Cell & Gene Engineering Corp's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vcanbio Cell & Gene Engineering Corp's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vcanbio Cell & Gene Engineering Corp's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vcanbio Cell & Gene Engineering Corp’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

The Equity of Vcanbio Cell & Gene Engineering Corp is 3.71 B CNY in 2025.

The Equity of Vcanbio Cell & Gene Engineering Corp changed from 3.60 B CNY to 3.71 B CNY, representing a 3.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp